REFERENCES
1. Yang L, Tang Y, He F, et al. Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort. Front Pediatr. 2022;10:996213.
2. Huang X, Li Y, Feng H, Chen P, Liu W. Clinical characteristics of juvenile myasthenia gravis in Southern China. Front Neurol. 2018;9:77.
3. Vecchio D, Ramdas S, Munot P, et al. Paediatric myasthenia gravis: prognostic factors for drug free remission. Neuromuscul Disord. 2020;30:120-7.
4. Sugimoto T, Ochi K, Ishikawa R, et al. Initial deterioration and intravenous methylprednisolone therapy in patients with myasthenia gravis. J Neurol Sci. 2020;412:116740.
5. Barraud C, Desguerre I, Barnerias C, Gitiaux C, Boulay C, Chabrol B. Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle Nerve. 2018;57:603-9.
6. Europa TA, Nel M, Heckmann JM. Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies. Muscle Nerve. 2018;58:542-9.
7. Braz NFT, Rocha NP, Vieira ÉLM, et al. Negative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravis. Neurol Sci. 2017;38:1405-13.
8. Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011;2011:404101.
9. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064-9.
10. Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367:904-12.
11. Pu JQ, Zhang JW, Chen RM, et al. Survey of height and weight of children and adolescents at different Tanner stages in urban China. Zhonghua Er Ke Za Zhi. 2021;59:1065-73.
12. Luo ZC, Low LCK, Karlberg J. A comparison of target height estimated and final height attained between Swedish and Hong Kong Chinese children. Acta Paediatr. 1999;88:248-52.
